Inovio Pharmaceuticals Inc (NASDAQ:INO) To Advance Development Of Ebola Vaccine To Human Trials

Boston, MA 09/25/2014 (wallstreetpr) – Inovio Pharmaceuticals Inc (NASDAQ:INO) and Seoul-based GeneOne Life Science Inc (KRX:011000) have announced plans to conduct human trial on Ebola vaccine by 2015. Inovio and GeneOne have advanced to the next level with their Ebola treating DNA vaccine and are seeking to start human trails by the next year. The two […]

New Developments: Seadrill (SDRL), QUALCOMM (QCOM), GlaxoSmithKline (GSK)

Boston, MA 09/24/2014 (wallstreetpr) – Seadrill Ltd (NYSE:SDRL) saw one of its significant investors increasing his stake in the $13.13 billion offshore drilling business. Billionaire, John Fredriksen, bought 2 million more shares in Seadrill (SDRL) through his investment vehicle known as Hemen Holding Ltd. The latest acquisition brings his stake in the company to 115.1 […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Earns $500 Million Slap In China

Boston, MA 09/19/2014 (wallstreetpr) – GlaxoSmithKline plc (ADR) (NYSE:GSK) is set to pay for more than it allegedly illegally consumed in China. The $113 billion British pharmaceutical giant will have to part with nearly $500 million to settle claims of bribery that earned it about $150 million in revenue, BBC News reported in an article. […]

EBOLA Vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Be Tasted Soon on Humans

Boston, MA 08/28/2014 (wallstreetpr) – EBOLA has created a huge buzz around the world in very limited time. Hundreds of people have died due to this deadly virus which has not any cure. Scientists from all around the world have been trying their best to find any vaccine for EBOLA virus for a long time […]

Buyers Line Up For InterMune Inc (NASDAQ:ITMN) As Shares Jump 14%

Boston, MA 08/14/2014 (wallstreetpr) –Shares of the lung drug developer, InterMune Inc (NASDAQ:ITMN), ended on a positive note on Wednesday, jumping 14.44% to $52.06. All that happened while potential buyers continued to circle the company with buyout agenda. People with insider knowledge have identified a number of European drug companies that include Sanofi and Roche […]

Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon

Boston, MA 08/11/2014 (wallstreetpr) – Ebola Virus has already caused thousands of deaths in all parts of the world, especially in Europe and African countries, but drug makers are yet to find out the vaccine. In amidst of deaths all around the world, reports about GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s new vaccine for Ebola can be a […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Employees under Probe Over Bribery Allegations

Boston, MA 07/28/2014 (wallstreetpr) – GlaxoSmithKline plc (ADR) (NYSE:GSK) employees are reported to have been the subject of an investigation carried out by the FBI on bribery allegations made against the company on its operations in China and Syria. The Department of Justice (DOJ) has also carried out its own investigations on the company’s operation […]

Johnson & Johnson (NYSE:JNJ) Loses Money In China, Jumps Into Another Problem In Chicago

Boston, MA 06/06/2014 (wallstreetpr) – The year 2014 does not seem to be an easy one for the world’s biggest healthcare products maker Johnson & Johnson (NYSE:JNJ), at least going by the recent developments.  While the company’s ability to generate profits is hard to dismiss, JNJ is somewhat under siege and may end up losing its […]

Glaxo SmithKline plc (ADR) (NYSE:GSK) Strikes Deal On Cancer Drug Venture

Boston, MA 06/04/2014 (wallstreetpr) – Developer and manufacturer of global healthcare products, Glaxo SmithKline plc (ADR) (NYSE:GSK) has struck a deal with biotechnology and privately-held company, Adaptimmune, for the development of a drug for cancer. Cancer Drug Glaxo SmithKline’s deal with Adaptimmune is reportedly worth over $350 million that is spread over a period of […]

Most Mentioned Stocks: Altria Group Inc (NYSE:MO), Health Care REIT, Inc. (NYSE:HCN), Pharmacyclics, Inc. (NASDAQ:PCYC)

Boston, MA 06/03/2014 (wallstreetpr) – Altria Group Inc (NYSE:MO) will pay a quarterly dividend of $0.48 per share on July 10, to shareholders who will have acquired its share by June 16. The newly declared quarterly dividend represents 4.73 percent on annualized basis.  The company has kept a good fight in the cigarette industry, and […]

Start Due Diligence Here: Strayer Education Inc (NASDAQ:STRA), American Caresource Holdings, Inc. (NASDAQ:ANCI), Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

Boston, MA 05/19/2014 (wallstreetpr) – After reporting 1Q2014 results that exceeded Wall Street estimates, Strayer Education Inc (NASDAQ:STRA) looks forward to undertaking more cost reduction efforts to support financial savings and maximize shareholder value. The company intends to save $50 million in operating expenses every year. The post-secondary education provider earned $1.40 per share in […]

Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical

Boston, MA 05/15/2014 (wallstreetpr) – The Switzerland-based drug giant Novartis AG (ADR) (NYSE:NVS) has reached another milestone with the latest patent litigation settlement in the U.S.  The company reached a settlement with the U.S. subsidiary of Sun Pharmaceutical Industries.  The agreement touches on the development of a generic version of Gleevec, a patented prescription drug […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) – Fails To Prove Its Strength In The 1Q2014

Boston, MA 05/07/2014 (wallstreetpr) – GlaxoSmithKline plc (ADR) (NYSE:GSK), the U.K. based biggest drug-maker expressed its happiness after the company remained as ‘interested observer’. The CEO, Andrew Witty, said that it was a joyous moment for the company, not to directly involve with the rivalry AstraZeneca Plc on the basis of the potential sale.  Critical […]

Novartis AG (ADR) (NYSE:NVS) Reverses Gear On Acquisition Deal

Boston, MA 05/05/2014 (wallstreetpr) – The Swiss-based Novartis AG (ADR) (NYSE:NVS) was due to acquire the ownership of Jerusalem-based Gamida Cell, a stem cell technology company. However, that transaction is off, according to the parent companies of Gamida. Novartis was planned to take over the full ownership of Gamida in a sale transaction valued at $600 […]

Merck & Co., Inc. (NYSE:MRK) In $14 Billion Asset Sale Talks With Bayer AG

Boston, MA 05/02/2014 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) is reported to be in exclusive asset sale talks with the German pharmaceutical giant Bayer AG, according to the people with insider knowledge. Talks with Bayer for the sale of Merck’s over-the-counter business comes on the back of a withdrawal of one of the front bidders. […]